Tenapanor: Phase IIb amended

Ardelyx said FDA recommended at an end-of-Phase II meeting that the company use its ongoing, double-blind, placebo-controlled, U.S. Phase IIb trial of twice-daily oral tenapanor to serve as 1 of 2 reg...